CCMB

Uppal Kalan, India
Uppal Kalan, India
SEARCH FILTERS
Time filter
Source Type

HYDERABAD, India, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in precision diagnostics for oncology, announced today that Cancer Genetics India (CG India) and CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB) have jointly organized the 2nd Annual NGS Conference taking place from 22nd to 24th of February 2017 in Hyderabad, India. The conference will bring together eminent scientists from several government research institutions that conduct cutting edge biological research using NGS technology and bioinformatics. The objective of the conference is to provide recent updates and discuss the impact of diverse yet relevant applications of NGS and bioinformatics on key research areas such as agri-genomics, onco-genomics, microbiology, and human genetics. The opening day of the conference coincided with the 89th birthday of Dr. P. M. Bhargava, the founder of CSIR-CCMB. On this occasion, CSIR-CCMB had organized a “Founder’s Day Celebration,” which was a great opportunity to interact with one of India’s most celebrated scientists. “We are delighted to partner with CG India to welcome all speakers and participants to hear from Dr. T Ramasamy, the distinguished speaker on this occasion,” said Dr. Rakesh Mishra, Director, CSIR-CCMB. “We are looking forward to a great conference that will promote cross-disciplinary research collaborations across India.” Comprehensive genomics services are central to CG India’s business model and are at the forefront of several scientific investigations carried out by scientists at CSIR-CCMB. Together, the two organizations believe that this platform will foster productive research collaborations that improve human health. CG India’s state-of-the-art facility, extensive expertise in developing customized NGS protocols, experience with routine assays, and comprehensive capabilities in analyzing NGS data will greatly support such research collaborations. “We are excited about this event and look forward to support and fulfill the scientific demands of leading scientists in the area of genomics, by providing high quality NGS and bioinformatics services,” said Mr. Panna Sharma, CEO and President of CGI. “As we help molecular oncologists gain novel insights in the molecular epidemiology of certain cancers in the Indian context, we look forward to developing research and clinical collaborations with leading cancer research centers and academic institutions.” The conference will highlight work in the area of genomics- driven findings in oncology to promote awareness about cancer related discoveries and explore how they may translate into personalized oncology applications. For more information, please visit http://cgiindia.in/NGSSymposium/. ABOUT CANCER GENETICS Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. For more information, please visit or follow CGI at: Internet: www.cancergenetics.com Twitter: @Cancer_Genetics Facebook: Cancer Genetics, Inc. or CG India Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding the completion, timing, pricing and size of the offering described in this press release constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 and the Form 10-Q for the Quarter ended March 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.


Singh S.K.,CCMB | Rakesh K.S.,CCMB | Ramamoorthy K.,CCMB | Saradhi A.V.P.,CCMB | Idris M.M.,CCMB
Journal of Proteomics and Bioinformatics | Year: 2010

The zebrafish (Danio rerio) is the extensively used alternate vertebrate model animal for understanding the brain function, development and evolution. Detailed brain proteome map of zebrafish is still not known inspite of its broad usage in developmental and neurological studies. We present here the large scale proteome profile of the zebrafish brain at the normal condition based on gel LC ESI MS/MS analysis. A total of 8475 different proteins details were identified based on this study with less than 1% false positive rate. All the proteins details obtained from this study were duly submitted to the database for validation and obtained accession numbers. The various proteins identified in this study were found to be involved in different biological activities, neurological functions and network pathways. With the availability of genomics information, this extensive study of proteomic profile of zebrafish brain tissue provided a complete view and details about the various proteins expressed in brain at the basal state. This study can lead to understand various new biomarkers underlying for various biological characteristics like development and neurological disease. © 2010 Singh SK, et al.


Singh S.K.,W309 | Sundaram C.S.,CCMB | Shanbhag S.,W309 | Idris M.M.,W309
Zebrafish | Year: 2010

Zebrafish is one of the most widely studied model organisms for understanding the neurodevelopment and neurological disorders of humans because of its similar brain structure, genome, and proteome. Understanding the zebrafish brain proteome is particularly useful as no data of zebrafish brain proteome are available despite its wide use as an alternative neurological animal model. We have determined the proteome profile of the zebrafish brain based on two-dimensional gel electrophoresis covering 161 proteins including 96 protein identities reported to the Swiss-Prot database. The proteins identified in this study were found to be associated with various pathways such as cell death, free radical scavenging, cell signaling, nervous system development, and cell cycle. The identified proteins were also observed to play important roles in various brain-related diseases and genetic disorders, such as Huntington's disease, Parkinson's disease, and schizophrenia. This article provides the zebrafish brain two-dimensional gel electrophoresis proteome map and the details of the 161 brain tissue-specific proteins. Also we have established the roles of the identified proteins in various neurological functions and diseases based on pathway analysis. © Copyright 2010, Mary Ann Liebert, Inc.


Zebrafish is one of the most widely studied model organisms for understanding the neurodevelopment and neurological disorders of humans because of its similar brain structure, genome, and proteome. Understanding the zebrafish brain proteome is particularly useful as no data of zebrafish brain proteome are available despite its wide use as an alternative neurological animal model. We have determined the proteome profile of the zebrafish brain based on two-dimensional gel electrophoresis covering 161 proteins including 96 protein identities reported to the Swiss-Prot database. The proteins identified in this study were found to be associated with various pathways such as cell death, free radical scavenging, cell signaling, nervous system development, and cell cycle. The identified proteins were also observed to play important roles in various brain-related diseases and genetic disorders, such as Huntingtons disease, Parkinsons disease, and schizophrenia. This article provides the zebrafish brain two-dimensional gel electrophoresis proteome map and the details of the 161 brain tissue-specific proteins. Also we have established the roles of the identified proteins in various neurological functions and diseases based on pathway analysis.

Loading CCMB collaborators
Loading CCMB collaborators